# Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk

Study · id `cardio:ct-nct01953328` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01953328](<https://clinicaltrials.gov/study/NCT01953328>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01953328

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 409 participants.

## Technical summary

Registry record NCT01953328. Randomized; triple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2015-12-23.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 409 participants (enrolled count; ClinicalTrials.gov record NCT01953328, source copy `cardio:ctgov-nct01953328-2015-12-23`, retrieved 2026-10-31)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT01953328, source copy `cardio:ctgov-nct01953328-2015-12-23`, retrieved 2026-10-31)
- Primary completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01953328, source copy `cardio:ctgov-nct01953328-2015-12-23`, retrieved 2026-10-31)
- Completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01953328, source copy `cardio:ctgov-nct01953328-2015-12-23`, retrieved 2026-10-31)
- Results first posted: 2015-12-23 (ClinicalTrials.gov record NCT01953328, source copy `cardio:ctgov-nct01953328-2015-12-23`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT01953328, source copy `cardio:ctgov-nct01953328-2015-12-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01953328-2015-12-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
- Acronym: AMG145
- Condition: Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
- Intervention (Drug): Atorvastatin
- Intervention (Biological): Evolocumab
- Intervention (Other): Placebo to Evolocumab
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 34e8ccab6fa0f5a8fd60b0f4ca976d2c97a2c720f4946f925f0185f248c769ee
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
